- Home
- SHOT vs GBIO Comparison
SHOT vs GBIO Comparison
Compare SHOT & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOT
- GBIO
- Stock Information
- Founded
- SHOT 2018
- GBIO 2016
- Country
- SHOT United States
- GBIO United States
- Employees
- SHOT N/A
- GBIO N/A
- Industry
- SHOT Biotechnology: Pharmaceutical Preparations
- GBIO Biotechnology: Pharmaceutical Preparations
- Sector
- SHOT Health Care
- GBIO Health Care
- Exchange
- SHOT Nasdaq
- GBIO Nasdaq
- Market Cap
- SHOT 30.4M
- GBIO 29.2M
- IPO Year
- SHOT 2020
- GBIO 2020
- Fundamental
- Price
- SHOT $0.39
- GBIO $0.35
- Analyst Decision
- SHOT
- GBIO Strong Buy
- Analyst Count
- SHOT 0
- GBIO 4
- Target Price
- SHOT N/A
- GBIO $7.33
- AVG Volume (30 Days)
- SHOT 6.1M
- GBIO 1.1M
- Earning Date
- SHOT 08-13-2025
- GBIO 08-06-2025
- Dividend Yield
- SHOT N/A
- GBIO N/A
- EPS Growth
- SHOT N/A
- GBIO N/A
- EPS
- SHOT N/A
- GBIO N/A
- Revenue
- SHOT $573,336.00
- GBIO $24,556,000.00
- Revenue This Year
- SHOT N/A
- GBIO N/A
- Revenue Next Year
- SHOT N/A
- GBIO N/A
- P/E Ratio
- SHOT N/A
- GBIO N/A
- Revenue Growth
- SHOT 69.32
- GBIO 146.47
- 52 Week Low
- SHOT $0.23
- GBIO $0.30
- 52 Week High
- SHOT $1.77
- GBIO $3.65
- Technical
- Relative Strength Index (RSI)
- SHOT 55.28
- GBIO 48.05
- Support Level
- SHOT $0.35
- GBIO $0.32
- Resistance Level
- SHOT $0.48
- GBIO $0.36
- Average True Range (ATR)
- SHOT 0.07
- GBIO 0.03
- MACD
- SHOT 0.02
- GBIO -0.00
- Stochastic Oscillator
- SHOT 53.64
- GBIO 48.09
About SHOT Safety Shot Inc.
Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.